EN
登录

合成生物学初创公司Enduro Genetics筹集1200万欧元A轮融资,扩大其生物生产平台

Enduro Genetics Raises €12 Million to Expand Its Bioproduction Platform

GEN 等信源发布 2025-02-04 01:09

可切换为仅中文


Enduro Genetics, a synthetic biology startup, raised €12 million ($12.4 million) in Series A funding from Supernova Invest, NOON Ventures, and Sandwater. The funding will be used to expand Enduro’s platform and scale commercialization.

合成生物学初创公司Enduro Genetics从Supernova Invest、NOON Ventures和Sandwater获得了1200万欧元(1240万美元)的a系列资金。这笔资金将用于扩大Enduro的平台和规模商业化。

Christian Munch, CEO, Enduro Genetics

Christian Munch,Enduro Genetics首席执行官

According to CEO Christian Munch, Enduro is addressing a problem that has challenged the global biomanufacturing industry for decades: declining productivity at industrial scale. The estimated €400 ($412.5) billion market, encompassing everything from industrial enzymes, biodegradable materials, alternative proteins, and pharmaceuticals, depends on genetically engineered microorganisms to produce these compounds..

根据首席执行官克里斯蒂安·蒙奇(ChristianMunch)的说法,Enduro正在解决一个挑战全球生物制造业数十年的问题:工业规模生产力下降。据估计,这一价值400亿欧元(4125亿美元)的市场,涵盖了从工业酶、可生物降解材料、替代蛋白质和药物等一切,依赖基因工程微生物来生产这些化合物。。

Despite best efforts to optimize genetic strains, large-scale industrial processes create conditions that drive microorganisms to mutate, creating cell-to-cell variation, as cells prioritize their survival over production, he explained. These non-productive cells proliferate, outcompeting the productive cells for space and nutrients, until ultimately all the productive cells are gone.

他解释说,尽管尽最大努力优化遗传菌株,但大规模的工业过程创造了驱动微生物突变的条件,产生了细胞间的变异,因为细胞优先于生产。这些非生产性细胞增殖,在空间和营养方面超过生产性细胞,直到最终所有生产性细胞都消失。

This causes a significant drop-off in yield over the production cycle, impacting profitability and reducing efficiency, explained Munch..

Munch解释说,这会导致整个生产周期的产量大幅下降,影响盈利能力并降低效率。。

Universal bioproduction at scale

大规模通用生物生产

Enduro’s patented “synthetic addiction” technology, created by founder and CSO Peter Rugbjerg, PhD, integrates a genetic plug-in into the microbial production host, coupling each cell’s productivity to its health and growth. This ensures that only high-producing cells can survive and thrive, effectively eliminating non-productive cells from the population, maintains Rugbjerg.

Enduro的专利“合成成瘾”技术由创始人兼CSO Peter Rugbjerg博士创建,将基因插件整合到微生物生产宿主中,将每个细胞的生产力与其健康和生长联系起来。Rugbjerg认为,这确保了只有高产细胞才能存活和繁殖,从而有效地从人群中消除了非生产性细胞。

By maintaining a stable and productive microbial community, Enduro Sense unlocks the full potential of industrial biomanufacturing, enabling consistent, scalable, and cost-efficient production, he added. Rugbjerg’s research into synthetic addiction has been published in .

他补充说,通过维持一个稳定而高效的微生物群落,Enduro Sense释放了工业生物制造的全部潜力,实现了一致、可扩展和成本效益高的生产。Rugbjerg对合成成瘾的研究发表在。

Nature

自然

and

PNAS

PNAS

.

.

Enduro Sense is applicable for all expression systems where the production confers a burden on the microbial host, irrespective of organism or product type, and can be used in established processes as well as new processes under development, claim company officials, who point out that this enables Enduro’s customers to produce existing products more efficiently and drive innovation by accelerating the development and commercialization of new product lines..

Enduro Sense适用于所有表达系统,在这些系统中,生产会给微生物宿主带来负担,无论是生物体还是产品类型,并且可以用于已建立的过程以及正在开发的新过程,公司官员声称,这使Enduro的客户能够更有效地生产现有产品,并通过加速新产品线的开发和商业化来推动创新。。

Enduro is commercializing its technology at a pivotal time when industries are embracing biomanufacturing to decarbonize and create sustainable alternatives to fossil-based products, such as bio-based fuels, bioplastics, specialty chemicals, alternative proteins, and pharmaceuticals.

Enduro正在将其技术商业化,此时各行业正在拥抱生物制造,以脱碳并创造可持续的化石产品替代品,如生物基燃料、生物塑料、特种化学品、替代蛋白质和药物。

Peter Rugbjerg, PhD, CSO and Founder, Enduro Genetics

Peter Rugbjerg,博士,CSO和Enduro Genetics创始人

The startup already counts clients including biomanufacturers from both the biopharma and food, agriculture, and industrial space. The new funding takes the total raised by Enduro to €18 million ($18.6 million) including grants from the BioInnovation Institute and the European Innovation Council accelerator grant and will be used to expand Enduro’s technology platform and accelerate commercialization..

这家初创公司已经拥有包括生物制药、食品、农业和工业领域的生物制造商在内的众多客户。新资金使Enduro筹集的资金总额达到1800万欧元(1860万美元),其中包括生物创新研究所和欧洲创新委员会加速器拨款,并将用于扩大Enduro的技术平台和加速商业化。。

“This new fundraise is a key milestone for Enduro,” said Munch. “It allows us to accelerate our commercialization efforts, strengthen our technology platform, and expand the technology for use in biopharmaceutical expression systems.”

Munch说:“这次新的筹资活动是Enduro的一个关键里程碑。”。“它使我们能够加速商业化努力,加强我们的技术平台,并扩展用于生物制药表达系统的技术。”

“Solving the cell-to-cell biomanufacturing challenge has plagued academia and industry for decades,” pointed out Rugbjerg. “Too many companies have been limited by the fact that only a minority of cells used in bioprocesses today contribute to high production.”

Rugbjerg指出:“几十年来,解决细胞间生物制造挑战一直困扰着学术界和工业界。太多的公司受到限制,因为今天生物过程中使用的细胞只有少数有助于高产。”

“Enduro’s novel technology could act as a critical enabler to break the cost barrier of biosolutions for a massive application into the food and chemical industries,” according to Romain Sautrau, investment director at Supernova Invest. “We were impressed not only with the technology but also the team’s traction in such a short time bringing on board leading biomanufacturing companies.

超新星投资公司(Supernova Invest)投资总监罗曼·索特罗(Romain Sautrau)表示:“Enduro的新技术可能成为打破生物解决方案成本壁垒的关键因素,可以在食品和化学工业中大规模应用。”。“我们不仅对技术印象深刻,而且对团队在如此短的时间内吸引领先生物制造公司的吸引力印象深刻。

We look forward to working closely with Christian and Peter to support their growth journey.”.

我们期待着与克里斯蒂安和彼得密切合作,支持他们的成长之旅。”。

“We’re delighted to double down on our investment in Enduro in their Series A round,” stated Theis Malmborg, general partner at NOON Ventures. “Enduro’s cell reprogramming technology is solving major challenges in the bioproduction space and large organizations are already starting to reap the benefits.

NOON Ventures的普通合伙人泰斯·马尔姆博格(Theis Malmborg)表示:“我们很高兴在A轮耐力赛中将我们对耐力赛的投资翻了一番。”。“Enduro的细胞重编程技术正在解决生物生产领域的重大挑战,大型组织已经开始受益。

We believe the team will have an outsized impact on the future of biomanufacturing, and we are excited to be a part of that journey with them.”.

我们相信该团队将对生物制造的未来产生巨大影响,我们很高兴能与他们一起参与这一旅程。”。

News

新闻